Xeloda, Capecitabine Newswire (Page 3)

Xeloda, Capecitabine Newswire (Page 3)

Comprehensive Real-Time News Feed for Xeloda, Capecitabine (generic). (Page 3)

Results 41 - 60 of 183 in Xeloda, Capecitabine (generic)

  1. Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in ...Read the original story

    Dec 7, 2016 | Customer Interaction Solutions

    Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response at 10 Months in Third-line Setting for Patients With and Without Brain Metastases SAN ANTONIO, Texas, Dec. 07, 2016 -- Cascadian Therapeutics, Inc. , a clinical-stage biopharmaceutical company, today announced that following a recent meeting with the U.S. Food and Drug Administration and discussions with the Company's external Steering Committee, it has amended the HER2CLIMB Phase 2 clinical trial of tucatinib by increasing the sample size so that, if successful, the trial could serve as a single pivotal study to support registration.

    Comment?

  2. New Study Explores Market Pipeline Analysis of Salivary Gland Cancer in H2 2016Read the original story

    Dec 4, 2016 | PR.com

    The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action , route of administration and molecule type. Albany, NY, December 04, 2016 -- -- A latest pipeline review has been provided by Global Direct Market's research store.

    Comment?

  3. Patheon buys Roche's Xeloda API plant and signs supply dealRead the original story w/Photo

    Nov 29, 2016 | Drug Researcher

    Patheon has bought a US API facility from Roche in a deal that will also see the CMO supply the Swiss firm with drug ingredients. The facility in question is in Florence, South Carolina.

    Comment?

  4. Down 11.7%: Is Celldex Therapeutics Now a Buy?Read the original story w/Photo

    Nov 29, 2016 | Fox News

    Celldex's stock has been extremely volatile this month due to a slew of factors. First off, the biotech's stock got a welcome boost as a result of Hillary Clinton's unexpected loss earlier this month, implying that dramatic changes to U.S. drug pricing schemes are off the table for the time being.

    Comment?

  5. Global Capecitabine (CAS 154361-50-9) Market Growth, Development and...Read the original story

    Nov 29, 2016 | Emailwire.com

    ReportsWeb has announced the addition of the 'Capecitabine Industry Global and Chinese Market Scenario 2016-2021' report to their offering. This report provides Capecitabine industry analysis for the international markets includ This is a professional and in-depth study on the current state of the Global Capecitabine Industry with a focus on the Chinese market.

    Comment?

  6. Cascadian Therapeutics Announces Stockholders And Board Of Directors Approve Reverse Stock SplitRead the original story

    Nov 27, 2016 | BioSpace

    Cascadian Therapeutics, Inc. , a clinical-stage biopharmaceutical company, today announced that at a special meeting held on November 18, 2016, stockholders voted to approve a proposal authorizing the board of directors of the Company to effect a reverse stock split of the Company's outstanding common shares at a ratio of 1-for-6, and a reduction in the number of authorized shares of common stock from 200.0 million shares to 66.7 million shares. The Company believes the change in authorized shares will provide sufficient capacity to support its programs.

    Comment?

  7. Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock SplitRead the original story

    Nov 23, 2016 | Customer Interaction Solutions

    Cascadian Therapeutics, Inc. , a clinical-stage biopharmaceutical company, today announced that at a special meeting held on November 18, 2016, stockholders voted to approve a proposal authorizing the board of directors of the Company to effect a reverse stock split of the Company's outstanding common shares at a ratio of 1-for-6, and a reduction in the number of authorized shares of common stock from 200.0 million shares to 66.7 million shares. The Company believes the change in authorized shares will provide sufficient capacity to support its programs.

    Comment?

  8. Cascadian Therapeutics Announces Presentations of Updated Clinical...Read the original story

    Nov 15, 2016 | P&T Community

    Cascadian Therapeutics, Inc. , a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company's lead product candidate tucatinib will be presented at the 2016 San Antonio Breast Cancer Symposium to be held December 6-10 in San Antonio, TX. The Phase 1b "Triplet" poster presentation will include more mature progression-free survival and safety data not included in the abstract posted on the SABCS website, which was as of May 2016.

    Comment?

  9. Global HER2-Negative Breast Cancer Market to Grow at a CAGR of 15.94% over Forecast Period 2015-2019Read the original story w/Photo

    Nov 11, 2016 | SBWire

    HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer.

    Comment?

  10. Presurgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancerRead the original story w/Photo

    Nov 9, 2016 | PhysOrg Weblog

    Neoadjuvant endocrine therapy - designed to reduce the size of breast tumors before surgical removal - appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor -positive breast cancer with considerably fewer side effects. The study conducted by a Massachusetts General Hospital Cancer Center research team appears in the current print issue of JAMA Oncology and was published online earlier this year.

    Comment?

  11. Tailored, dense-dose chemotherapy for early breast cancer does not result in significant improvementRead the original story w/Photo

    Nov 8, 2016 | PhysOrg Weblog

    Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival, and nonhematologic toxic effects were more frequent in the tailored dose-dense group, according to a study appearing in the November 8 issue of JAMA . Dose-dense therapy, defined as delivery of chemotherapy at shorter intervals without increasing the cumulative dose, has been suggested as a means to improve efficacy of chemotherapy for early breast cancer .

    Comment?

  12. Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate UpdateRead the original story

    Nov 7, 2016 | Customer Interaction Solutions

    Cascadian Therapeutics , a clinical-stage biopharmaceutical company, today provided third quarter highlights and reported financial results for the quarter ended September 30, 2016. "We continue to make strides on the clinical development front as we advance tucatinib in combination for patients with metastatic HER2+ breast cancer, including those with and without brain metastases," said Scott Myers, CEO of Cascadian Therapeutics.

    Comment?

  13. First breast cancer drug in decade approved for NHS useRead the original story w/Photo

    Nov 3, 2016 | Sunday Herald

    Bringing you the best journalism, comment and analysis in Scotland, wherever and whenever you need it, in a format to suit you. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

    Comment?

  14. Calls for investigation into claims of 'vetting' for submissions to hospital chemotherapy inquiryRead the original story w/Photo

    Oct 25, 2016 | The Age

    The clerk of the NSW parliament has been asked to investigate claims health department employees were required to get approval from senior bureaucrats before making submissions to an inquiry into under-dosing of chemotherapy patients at Sydney hospitals. MPs have asked the clerk to investigate whether the inquiry into the widening under-dosing affair has been stymied after a claim was made that employees in eight south-eastern Sydney hospitals were told to secure approval from the health district's CEO and the department before submitting statements.

    Comment?

  15. Parliament clerk to investigate claims inquiry submissions pre-approvedRead the original story w/Photo

    Oct 25, 2016 | Sydney Morning Herald

    Skip to navigation Skip to content Skip to footer View text version of this page Help using this website - Accessibility statement Join today and you can easily save your favourite articles, join in the conversation and comment, plus select which news your want direct to your inbox. The clerk of the NSW parliament has been asked to investigate claims health department employees were required to get approval from senior bureaucrats before making submissions to an inquiry into under-dosing of chemotherapy patients at Sydney hospitals.

    Comment?

  16. A phase 3 trial evaluating panitumumab plus best supportive care vs...Read the original story

    Oct 13, 2016 | British Journal of Cancer

    We assessed the treatment effect of panitumumab plus best supportive care vs BSC on overall survival in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer and report the first prospective extended RAS analysis in a phase 3 trial. kg−1 Q2W) plus BSC or BSC.

    Comment?

  17. Breast cancer drug shows potential in patients with skin metastasesRead the original story w/Photo

    Oct 14, 2016 | Medical News Today

    Researchers are reporting clinical activity with the investigational oral compound tucatinib, used as part of combination therapy in patients with advanced breast cancer and skin metastases. The findings, from a small group of patients enrolled in a Phase Ib study, were presented at the European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark.

    Comment?

  18. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel...Read the original story w/Photo

    Oct 9, 2016 | BioMed Central

    SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

    Comment?

  19. Phase II study of TP300 in patients with advanced gastric or...Read the original story w/Photo

    Oct 9, 2016 | BioMed Central

    TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability.

    Comment?

  20. Cascadian Therapeutics Announces Presentation Of Tucatinib In...Read the original story

    Oct 9, 2016 | BioSpace

    Cascadian Therapeutics , a clinical-stage biopharmaceutical company, today announced the presentation of clinical activity of tucatinib, its investigational, highly selective small molecule HER2 inhibitor, in combination therapy at the European Society for Medical Oncology 2016 Congress being held October 7-11, 2016 in Copenhagen, Denmark. Data from the poster presentation , an Oral HER2-Specific Inhibitor in Combination with Capecitabine and/or Trastuzumab in Third Line or Later Treatment"), reported on responses of skin lesions in HER2+ metastatic breast cancer patients following treatment with tucatinib in combination with capecitabine and/or trastuzumab.

    Comment?